Holter of Movement in Patients With Amyotrophic Lateral Sclerosis.
ConditionAmyotrophic Lateral Sclerosis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCentre Hospitalier Universitaire de Liege
About this trial
ActiALS is a multicentric academic study. Patients with amyotrophic lateral sclerosis (ALS) may be included on a voluntary basis. The investigators plan to include a group of approximately 30 patients with ALS.
The investigators have planned to assess patient every three months for a year. After each visit, participants will wear Actimyo for one month daily.
Eligibility criteria
Qualifiers
Clinically defined or probable diagnosis of ALS according to El Escorial criteria revised with Awaji's electro-diagnostic algorithm.
Over 18 years old.
Signed informed consent
If patient on Riluzole, the dosage should be stable for 1 month and continued throughout the study period.
Disqualifiers
Patients with excessive cognitive disorders, limiting the understanding of task or with apparent communication difficulties hindering data collection.
Any other previous or present pathology having an impact on motor function.
Recent surgery or trauma (less than 6 months) in the upper or lower limbs.
Prior neurological, endocrine, infectious, allergic, or chronic or acute inflammatory pathology in the three weeks preceding inclusion.
Trial design
Treatments tested in this trial
- Actimyo
Treatment groups
No treatment groups listed
Sponsors and collaborators
Centre Hospitalier Universitaire de Liege
Lead sponsor
SYSNAV
Collaborator
Source ClinicalTrials.gov